Strides Pharma Science has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, to the stock exchanges. The filing, made pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's environmental, social, and governance (ESG) performance. The report has undergone limited assurance verification by DNV Business Assurance India Private Limited.

Environmental Performance

The company reported a total energy consumption of 280,288,004,402 KJ for FY26, with 44.19% derived from renewable sources. Total Scope 1 and Scope 2 greenhouse gas emissions stood at 25,380.03 metric tonnes of CO2 equivalent. Water consumption for the year was recorded at 190,297.69 kilolitres, while total waste generated amounted to 1,910.28 metric tonnes. Of the total waste generated, 1,207.40 metric tonnes were recovered through recycling and other recovery operations, achieving a recovery rate of 63.21%.

Social and Governance Metrics

Strides Pharma Science employed a total workforce of 5,394 individuals, comprising 2,810 employees and 2,584 workers. The report highlighted a Lost Time Injury Frequency Rate (LTIFR) of 0.11 for employees, with zero fatalities recorded across the organization. The company spent 0.44% of its total revenue on well-being measures for employees and workers. Gross wages paid to females constituted 16% of the total wages paid by the entity.

Operational and Financial Disclosures

The company reported exports contributing 90.66% to its total turnover on a standalone basis. It conducted supplier assessments for 50 critical suppliers, accounting for 73.5% of its direct procurement value. The report also noted that the company is a signatory to the United Nations Global Compact and holds several ISO certifications, including ISO 14001, ISO 45001, and ISO 50001.

The report confirms compliance with applicable environmental laws and regulations, including the Water Act, Air Act, and Environment Protection Act. No fines or penalties were reported for non-compliance with these regulations during the financial year.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE939A01011/23f499a925d84a6a.pdf

Strides Pharma Science Limited has successfully completed the sale of a majority stake in its wholly owned subsidiary, Pivot Path Private Limited, to a consortium led by Ascent Capital and co-investor Vintage Classic. The transaction was executed for an aggregate consideration of approximately ₹1,000 million. Pursuant to the completion, Strides has received ₹750 million, with the balance consideration of ₹250 million payable on the first anniversary of the closing date. Consequent to this transaction, Pivot Path ceased to be a Wholly Owned Subsidiary of the company with effect from July 1, 2026, and shall henceforth be classified as an Associate Company.

The Board of Directors had approved the strategic investment at its meeting held on June 27, 2026. The deal, which also involved a primary infusion of approximately ₹500 million into Pivot Path by Ascent Capital, valued the entity at approximately ₹2,300 million on a post-money basis. The resultant capital structure sees Strides retain a 19.95% stake, while investors hold 65.05% and an ESOP Pool constitutes 15%.

Pivot Path originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC), and provides services in life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. The business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million.

Financial Contribution of Pivot Path

The following table details the contribution of Pivot Path to Strides' financials for FY 2025-26 on a post-demerger basis:

Transaction Structure

The deal comprised the divestment of a majority stake by Strides and the infusion of primary capital into Pivot Path. The investors, Ascent Growth Trust and Vintage Classic Limited, do not belong to the promoter, promoter group, or group companies of Strides Pharma Science Limited. The transaction was based on an independent valuation conducted by a SEBI-registered merchant banker.